Monitoring Treatment Response in Bone Metastases from Breast Cancer
Author Information
Author(s): C Blomqvist, L Risteli, J Risteli, P Virkkunen, S Sarna, I Elomaa
Primary Institution: University of Helsinki
Hypothesis
Can biochemical markers of type I collagen metabolism effectively monitor treatment response in patients with bone metastases from breast carcinoma?
Conclusion
Changes in the levels of collagen metabolites ICTP and PICP correlate with treatment response in patients with bone metastases from breast cancer.
Supporting Evidence
- Reduction in ICTP correlated significantly with treatment response at three months.
- PICP and ICTP changes differed significantly between patients with progressive disease and those with responding or stable metastases.
- Both ICTP and PICP showed statistically significant correlations to other markers of bone metabolism.
Takeaway
Doctors can check certain proteins in the blood to see how well treatment is working for breast cancer that has spread to the bones.
Methodology
Patients were monitored for treatment response using biochemical markers of bone metabolism and conventional radiography.
Limitations
The study only monitored biochemical markers during a 3-month period, which may not reflect early treatment responses.
Participant Demographics
Fifty normocalcaemic female patients with painful bone metastases from breast cancer.
Statistical Information
P-Value
P<0.0005 for ICTP change and treatment response; P=0.03 for PICP change and treatment response.
Confidence Interval
95% CI 0.22-0.72 for ICTP; 95% CI 0.26-0.74 for PICP.
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website